GEN Stock Overview
Provides DNA analysis and congenital diseases diagnostic services in Poland.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 4/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Genomed Spólka Akcyjna Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | zł29.20 |
| 52 Week High | zł37.20 |
| 52 Week Low | zł28.00 |
| Beta | -0.050 |
| 11 Month Change | 0.69% |
| 3 Month Change | 4.29% |
| 1 Year Change | -21.51% |
| 33 Year Change | -31.78% |
| 5 Year Change | 13.18% |
| Change since IPO | 4.29% |
Recent News & Updates
Recent updates
Shareholder Returns
| GEN | PL Biotechs | PL Market | |
|---|---|---|---|
| 7D | 0% | 1.7% | -0.7% |
| 1Y | -21.5% | -10.0% | 16.7% |
Return vs Industry: GEN underperformed the Polish Biotechs industry which returned -9.7% over the past year.
Return vs Market: GEN underperformed the Polish Market which returned 16% over the past year.
Price Volatility
| GEN volatility | |
|---|---|
| GEN Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 6.1% |
| Market Average Movement | 5.1% |
| 10% most volatile stocks in PL Market | 9.3% |
| 10% least volatile stocks in PL Market | 3.4% |
Stable Share Price: GEN has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine GEN's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2007 | 48 | Anna Boguszewska-Chachulska | www.genomed.pl |
Genomed Spólka Akcyjna provides DNA analysis and congenital diseases diagnostic services in Poland. It develops molecular diagnostics based on DNA sequencing for the application of prophylactics and treatment, such as replacement or gene therapy. The company also offers the analysis of mutations responsible for congenital diseases in approximately 6,500 genes; and next-generation sequencing technology.
Genomed Spólka Akcyjna Fundamentals Summary
| GEN fundamental statistics | |
|---|---|
| Market cap | zł38.58m |
| Earnings (TTM) | zł588.67k |
| Revenue (TTM) | zł22.14m |
65.5x
P/E Ratio1.7x
P/S RatioIs GEN overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| GEN income statement (TTM) | |
|---|---|
| Revenue | zł22.14m |
| Cost of Revenue | zł8.24m |
| Gross Profit | zł13.89m |
| Other Expenses | zł13.30m |
| Earnings | zł588.67k |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
Nov 13, 2024
| Earnings per share (EPS) | 0.45 |
| Gross Margin | 62.76% |
| Net Profit Margin | 2.66% |
| Debt/Equity Ratio | 0.008% |
How did GEN perform over the long term?
See historical performance and comparison